Fig. 2

Extension of treatment intervals following the switch to intravitreal faricimab. This figure depicts the change in median injection intervals from baseline (mo0, prior to the switch) to nine months after switching to Faricimab (mo9). The treatment interval significantly increased from 35 days (interquartile range (iqr): 15) at mo0 to 56 days (iqr: 20) at mo9, representing a 60% extension. Asterisks indicate the statistical significance of pairwise comparisons (**** p < 0.0001)